Literature DB >> 6093663

NIH conference. Rheumatoid arthritis: evolving concepts of pathogenesis and treatment.

J L Decker, D G Malone, B Haraoui, S M Wahl, L Schrieber, J H Klippel, A D Steinberg, R L Wilder.   

Abstract

Rheumatoid arthritis is a chronic inflammatory synovitis that primarily involves peripheral diarthrodial joints. Immunohistologic analysis of diseased synovium has shown a spectrum of abnormalities that resemble various stages of a cell-mediated, or delayed-type, immune reaction. The infiltrating mononuclear cells produce various factors that modulate adjacent tissues and appear to produce the characteristic destructive features of the disorder. Our understanding of the mechanisms of action of various therapeutic modes also indicates that the disease is primarily mediated by activated mononuclear cells. All effective therapies have been shown to affect either mononuclear cell function or the rates of production or elimination of these cells. The disorder likely represents the pathologic expression of a genetically controlled host immune response to an undefined causative stimulus. The stimulus could be an infectious agent(s), a product(s) derived from an infectious agent(s), a constituent(s) of synovial or connective tissue, or a combination of these.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6093663     DOI: 10.7326/0003-4819-101-6-810

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  36 in total

1.  Detection of circulating Fc epsilon R2/CD23+ monocytes in patients with rheumatic diseases.

Authors:  H Becker; P Potyka; C Weber; K Federlin
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

2.  Potency ratio, clinical equivalence, and wasting ratio estimate of different glucocorticoids.

Authors:  B Imbimbo; S Milani
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

3.  QuantiFERON testing for cell-mediated immunity to cytomegalovirus in patients with rheumatoid arthritis receiving abatacept and other DMARD therapy.

Authors:  Anthony S Russell; Luiz Lisboa; Marla F Dos Santos; Deepali Kumar; Atul Humar
Journal:  Clin Rheumatol       Date:  2013-06-11       Impact factor: 2.980

4.  Pulmonary gamma interferon production in patients with fibrosing alveolitis.

Authors:  B W Robinson; A H Rose
Journal:  Thorax       Date:  1990-02       Impact factor: 9.139

5.  Immunomodulating therapy of rheumatoid arthritis by high-dose intravenous immunoglobulin.

Authors:  H Becker; G Mitropoulou; K Helmke
Journal:  Klin Wochenschr       Date:  1989-03-01

6.  Decreased expression of CD7 occurs in rheumatoid arthritis.

Authors:  A I Lazarovits; J Karsh
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

Review 7.  Cyclosporine and rheumatoid arthritis.

Authors:  O Førre; K Waalen; H E Rugstad; K J Berg; D Solbu; E Kåss
Journal:  Springer Semin Immunopathol       Date:  1988

8.  Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  G Semenzato; L M Bambara; D Biasi; A Frigo; F Vinante; B Zuppini; L Trentin; C Feruglio; M Chilosi; G Pizzolo
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

9.  Functional characterization of SV40-transformed adherent synovial cells from rheumatoid arthritis.

Authors:  M Goto; M Okamoto; M Sasano; K Nishizawa; S Aotsuka; N Yamaguchi; M Obinata; K Ikeda
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

10.  Differentiation of human osteoblastic cells in culture: modulation of proteases by extracellular matrix and tumor necrosis factor-alpha.

Authors:  F S Panagakos; S Kumar
Journal:  Inflammation       Date:  1995-08       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.